Connection

GREG CUNY to Structure-Activity Relationship

This is a "connection" page, showing publications GREG CUNY has written about Structure-Activity Relationship.
Connection Strength

2.809
  1. Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition. Bioorg Med Chem Lett. 2023 06 15; 90:129328.
    View in: PubMed
    Score: 0.194
  2. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. Eur J Med Chem. 2020 Aug 15; 200:112417.
    View in: PubMed
    Score: 0.158
  3. Divergent Approach for the Synthesis of Gombamide A and Derivatives. Org Lett. 2016 09 16; 18(18):4726-9.
    View in: PubMed
    Score: 0.122
  4. Synthesis and Antiproliferative Activity Evaluation of the Disulfide-Containing Cyclic Peptide Thiochondrilline C and Derivatives. J Nat Prod. 2015 Oct 23; 78(10):2398-404.
    View in: PubMed
    Score: 0.115
  5. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2713-9.
    View in: PubMed
    Score: 0.111
  6. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase (CpIMPDH) inhibitors. J Med Chem. 2014 Dec 26; 57(24):10544-50.
    View in: PubMed
    Score: 0.108
  7. Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem. 2013 May 23; 56(10):4028-43.
    View in: PubMed
    Score: 0.097
  8. Selective and potent urea inhibitors of cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem. 2012 Sep 13; 55(17):7759-71.
    View in: PubMed
    Score: 0.093
  9. Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability. Bioorg Med Chem Lett. 2012 Sep 01; 22(17):5685-8.
    View in: PubMed
    Score: 0.092
  10. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett. 2012 Mar 01; 22(5):2015-9.
    View in: PubMed
    Score: 0.089
  11. Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett. 2012 Mar 01; 22(5):1985-8.
    View in: PubMed
    Score: 0.089
  12. Synthesis of fused imidazoles, pyrroles, and indoles with a defined stereocenter a to nitrogen utilizing Mitsunobu alkylation followed by palladium-catalyzed cyclization. J Org Chem. 2011 Oct 21; 76(20):8477-82.
    View in: PubMed
    Score: 0.087
  13. Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett. 2011 Oct 01; 21(19):5774-7.
    View in: PubMed
    Score: 0.086
  14. Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors. Bioorg Med Chem Lett. 2011 Apr 01; 21(7):2098-101.
    View in: PubMed
    Score: 0.083
  15. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15; 20(12):3491-4.
    View in: PubMed
    Score: 0.079
  16. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 01; 19(21):6122-6.
    View in: PubMed
    Score: 0.075
  17. Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem. 2009 Aug 13; 52(15):4623-30.
    View in: PubMed
    Score: 0.075
  18. One-pot synthesis of alpha-carbolines via sequential palladium-catalyzed aryl amination and intramolecular arylation. J Org Chem. 2009 Apr 17; 74(8):3152-5.
    View in: PubMed
    Score: 0.073
  19. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 01; 18(15):4388-92.
    View in: PubMed
    Score: 0.069
  20. Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors. Bioorg Med Chem Lett. 2008 Jun 01; 18(11):3219-23.
    View in: PubMed
    Score: 0.068
  21. Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6836-40.
    View in: PubMed
    Score: 0.066
  22. Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg Med Chem Lett. 2007 Jul 01; 17(13):3729-32.
    View in: PubMed
    Score: 0.064
  23. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19; 50(8):1886-95.
    View in: PubMed
    Score: 0.063
  24. Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett. 2005 Apr 01; 15(7):1885-9.
    View in: PubMed
    Score: 0.055
  25. Effects of a verbenachalcone derivative on neurite outgrowth, inhibition of caspase induction and gene expression. Bioorg Med Chem Lett. 2005 Feb 15; 15(4):1193-6.
    View in: PubMed
    Score: 0.055
  26. Nonhydrolyzable d-phenylalanine-benzoxazole derivatives retain antitubercular activity. Bioorg Med Chem Lett. 2023 01 15; 80:129116.
    View in: PubMed
    Score: 0.047
  27. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 11 01; 28(20):3356-3362.
    View in: PubMed
    Score: 0.035
  28. Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents. J Med Chem. 2018 06 14; 61(11):4739-4756.
    View in: PubMed
    Score: 0.034
  29. Optimization of a series of heterocycles as survival motor neuron gene transcription enhancers. Bioorg Med Chem Lett. 2017 12 01; 27(23):5144-5148.
    View in: PubMed
    Score: 0.033
  30. Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis. Antimicrob Agents Chemother. 2017 10; 61(10).
    View in: PubMed
    Score: 0.033
  31. Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. J Med Chem. 2017 06 08; 60(11):4594-4610.
    View in: PubMed
    Score: 0.032
  32. Structure of Cryptosporidium IMP dehydrogenase bound to an inhibitor with in vivo antiparasitic activity. Acta Crystallogr F Struct Biol Commun. 2015 May; 71(Pt 5):531-8.
    View in: PubMed
    Score: 0.028
  33. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 09; 57(19):7900-15.
    View in: PubMed
    Score: 0.027
  34. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013; 8(6):1291-302.
    View in: PubMed
    Score: 0.024
  35. Phthalazinone inhibitors of inosine-5'-monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem Lett. 2013 Feb 15; 23(4):1004-7.
    View in: PubMed
    Score: 0.024
  36. A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci (Elite Ed). 2012 06 01; 4(8):2701-8.
    View in: PubMed
    Score: 0.023
  37. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg. 2012 Aug; 115(2):297-304.
    View in: PubMed
    Score: 0.022
  38. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 08; 53(7):2709-18.
    View in: PubMed
    Score: 0.020
  39. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology. 2010 Mar; 112(3):637-44.
    View in: PubMed
    Score: 0.019
  40. Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus. Bioorg Med Chem Lett. 2010 Mar 01; 20(5):1767-70.
    View in: PubMed
    Score: 0.019
  41. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol. 2009 May 15; 182(10):6342-52.
    View in: PubMed
    Score: 0.018
  42. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008 May; 4(5):313-21.
    View in: PubMed
    Score: 0.017
  43. Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol. 2006 Apr 01; 176(7):4208-20.
    View in: PubMed
    Score: 0.015
  44. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15; 15(22):5039-44.
    View in: PubMed
    Score: 0.014
  45. Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol. 2005 Jul; 12(7):811-23.
    View in: PubMed
    Score: 0.014
  46. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep; 10(9):837-46.
    View in: PubMed
    Score: 0.012
  47. Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob Agents Chemother. 2003 Feb; 47(2):458-66.
    View in: PubMed
    Score: 0.012
  48. Potent in vitro methicillin-resistant Staphylococcus aureus activity of 2-(1H-indol-3-yl)quinoline derivatives. Bioorg Med Chem Lett. 2000 Dec 04; 10(23):2675-8.
    View in: PubMed
    Score: 0.010
  49. Ring opening cross-metathesis on solid support: a combinatorial library synthesis of highly functionalized cyclopentanes. Mol Divers. 1997-1998; 3(3):173-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.